US 12268694
Combination pharmaceutical agents as RSV inhibitors
granted A61KA61K31/4439A61K31/519
Quick answer
US patent 12268694 (Combination pharmaceutical agents as RSV inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Enanta Pharmaceuticals, Inc.
- Grant date
- Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K31/4439, A61K31/519, A61K31/55, A61K31/5513